

Biofilms: Microbes and Disease

Aparna, Madhu Sharma Pt.B.D. and Sarita Yadav

Department of Microbiology, Sharma PGIMS, Rohtak; Haryana, India

Bacteria that attach to surface aggregate in a hydrated polymeric matrix of their own synthesis to form biofilms. These represent microbial societies with their own defense and communication system. Transitioning from acute to chronic infection is frequently associated with biofilm formation. Bacteria in biofilms are innately more resistant to antimicrobial agents. The presence of indwelling medical devices increases the risk for biofilm formation and subsequent infection. The current antibiotic therapies are of limited effectiveness in resolving biofilms infection. This review attempts to discuss the stages in biofilm formation, their pathogenic mechanisms, effect of antimicrobial agents, detection and eradication of the biofilms.

Key-Words: Biofilms, staphylococci, *Pseudomonas*, *Candida*.

The concept of bacteria living within the context of a community rather than simply as autonomous entities is one that is quickly gaining acceptance. These communities of organisms living within extracellular matrix are known as biofilms. They can develop on abiotic and biotic surfaces, acting as a source of various infections. Biofilm development on surfaces is a dynamic stepwise process involving adhesion, growth, motility and extracellular polysaccharide production. The nature of biofilm and the physiological state of bacterial cells within the biofilm confers high level of resistance to antimicrobial agents. With the emergence of biofilm associated diseases, there are considerable diagnostic problems for the clinical laboratory. So, various techniques for detection and eradication of biofilms have been described.

Perhaps because many biofilms are sufficiently thick to be visible to the naked eye, these microbial communities were among the first to be studied by the late developing science of microbiology. Anton Van Leeuwenhoek scraped the plaque biofilm from his teeth and observed the "animalculi" that produced this microbial community with his primitive microscope. However, it was not until the 1970's that we began to appreciate that bacteria in the biofilm mode of existence, sessile bacteria, constitute a major component of the bacterial biomass in many environments, and it was not until the 1980s and 1990s that we began to appreciate that attached bacteria were organized in elaborate ways [1]. For e.g., different bacterial species specifically attach to different surfaces or co-aggregate with specific partners in the mouth. Often one species can co-aggregate with multiple partners, which themselves can aggregate with other partner to form a dense bacterial plaque. Advances in light microscopy coupled with developments in microelectrode technology have led to an appreciation that bacterial biofilms consist of microcolonies on a surface, and that within these microcolonies the bacteria have developed

Received on 7 August 2008; revised 28 November 2008.

Address for correspondence: Dr. Aparna. Associate Professor. Department of Microbiology. Pt. B.D. Sharma PGIMS, Rohtak – 124001. Haryana – India. E-mail: aparnaparmar2008@rediffmail.com.

The Brazilian Journal of Infectious Diseases 2008;12(6):526-530.
© 2008 by The Brazilian Journal of Infectious Diseases and Contexto Publishing. All rights reserved.

into organised communities with functional heterogeneity.

The organisms in a biofilm are specialised and have great deal of genetic energy. Given the selected pressures of certain environments, notably aquatic systems, biofilms are preferred method of growth. Their unique structure that evolves over time allows for a cohesive, robust community of cells with interspecies communication driven by the principle of survival. Microorganisms, be they are prokaryotic or eukaryotic, have the potential to live in one of the two phenotypes: sessile or planktonic. The sessile phenotype result from attachment and usually develops into a multispecies biofilm that has unique characteristics, making it similar in many ways to hydrated polymers. Planktonic are free – floating microorganisms [2]. These sessile biofilm communities can give rise to non sessile individuals, planktonic bacteria that can rapidly multiply and dispose. The common view is that planktonic bacteria must expose themselves to deleterious agents in their environment, be they phage or amoeba in nature, biocides in industrial settings or potent antimicrobial agents in a clinical setting. Since biofilms contaminate industrial pipelines, dental unit water lines, catheters, ventilators and medical implants, they act as a source of disease for humans, animals and plants. In this light, it is not surprising that an impressive number of chronic bacterial infections involve bacterial biofilms, which are not easily eradicated by conventional antibiotic therapy [1].

Stages in Biofilm Development

Biofilms like other communities form gradually over time. There is a five stage universal growth cycle of a biofilm with common characteristics independent of the phenotype of the organisms. Stage 1 is the attachment phase that can take only seconds to activate and is likely induced by environmental signals. These signals vary by organisms but they include changes in nutrients and nutrient concentrations, pH, temperature, oxygen concentration, osmolality and iron. Rough surfaces are more susceptible to biofilm formation this is likely due to reduction of shear forces and increased surface area. Studies indicate that biofilms also tend to form more readily on hydrophobic materials like teflon and other plastics than on glass and metal. The initial binding in stage I is reversible as some cells detach have the substraction. During


this stage, bacterial cells exhibit a logarithmic growth rate.

Stage II is characterized as irreversible binding and begins minutes after stage 1. After adhering to the epithelial surface, the bacteria begin to multiply while emitting chemical signals that “inter communicate” the bacterial cells. Once the signal intensity exceeds a certain threshold level, the genetic mechanisms underlying exopolysaccharide (EPS) production are activated which is able to trap nutrients and planktonic bacteria [1]. During stage II cell aggregates are formed and motility is decreased when cell aggregates become progressively layered with a thickness greater than 10 μm , the biofilm is in stage III also known as maturation I. When biofilms reach their ultimate thickness generally greater than 100 μm , this is called stage IV or maturation – 2. During stage V, cell dispersion is noted. Some of the bacteria develop the planktonic phenotype and leave the biofilm. This begins several days after stage IV [2].

Although certain constituents are common to all biofilms, the contribution of the host relative to the microorganisms such as immunologic components and the physical locations have an impact on this structure. Several key environmental and cultural characteristics affect the selection of multispecies biofilm inhabitants (Figure 1)

Much of the development and structural integrity of the

Figure 1. Environmental and cultural characteristics which affect the selection of biofilms multispecies.



biofilm is dependent upon quorum sensing (QS). QS is primarily a means with which extracellular molecules, pheromones, enhance communication among bacteria. The viability of the biofilm community is dependent upon stress response genes and cell signaling from the cells via QS or quorum diffusions. In *P. aeruginosa* it appears that an acylated homoserine lactone (acyl-HSL) is an important player in this type of cell to cell signaling [3]. Quorum sensing is widespread among several pathogenic and non pathogenic genera. Emerging evidence points to the involvement of quorum sensing in biofilm formation and surface motility in the opportunistic pathogens, *Pseudomonas aeruginosa*, *Burkholderia cepacia* and *Aeromonas hydrophilia*. Quorums

sensing genes are critical for pathogenesis of *P. aeruginosa* infection in the cystic fibrosis lung [4].

The three dimensional architecture of the mature biofilm has three layers and is comprised of stalks of mushroom – shaped microcolonies attached to the substratum surrounded by EPS. The biofilm matrix contains EPS, proteins and DNA; EPS constituents 50% to 90% of the organic carbon in the matrix. Many of the stalks and mushrooms together result in an architecture with water channels between the bacterial clusters. The water channels have been likened to a primitive circulatory system which protects cell bacteria against buildup of toxic metabolites and starvation while providing a source of nutrients [5].

Pathogenic Mechanisms

Different pathogenic mechanisms of the biofilms have been proposed. These include:

- Allow attachment to a solid surface;
- “Division of labor” increases metabolic efficiency of the community;
- Evade host defenses such as phagocytosis;
- Obtain a high density of microorganisms;
- Exchange genes that can result in more virulent strains of microorganisms;
- Produce a large concentration of toxins;
- Protect from antimicrobial agents;
- Detachment of microbial aggregates transmits microorganisms to other sites.

Biofilms develop preferentially on inert surfaces or on dead tissue, and occur commonly on medical devices and fragments of dead tissue such as sequestra of dead bone; they can also form on living tissues, as in the case of endocarditis [6]. Sessile bacterial cells release antigens and stimulate the production of antibodies, but the antibodies are not effective in killing bacteria within biofilms and may cause immune complex damage to surrounding tissues. Even in individuals with excellent cellular and humoral immune reactions, biofilm infections are rarely resolved by the host defense mechanisms [7].

More than half of the infectious diseases that affect mildly compromised individuals involves bacterial species that are commensals with the human body or are common in our environments. The surfaces of medical devices have been foci of device related infections showing the presence of large number of slime encased bacteria as evidenced by electron microscopy. Even the tissues taken from non device related chronic infections also show the presence of biofilm formation. These biofilm infections may be caused by a single species or by a mixture of species of bacteria or fungi (Table 1) [1,2].

Biofilms and Antimicrobial Agents

The armament of therapeutic agents available to treat bacterial infections today is restricted to antibiotics developed specifically to kill or stop the growth of individual bacteria.

Table 1. Partial list of human infections involving biofilms.

Infection or disease	Common biofilm bacterial species
Dental caries	Acidogenic Gram-positive cocci (e.g. <i>Streptococcus</i>)
Periodontitis	Gram-negative anaerobic oral bacteria
Otitis media	Nontypable strains of <i>Haemophilus influenzae</i>
Musculoskeletal infections	Gram-positive cocci (e.g., <i>Staphylococci</i>)
Necrotizing fasciitis	Group A <i>Streptococci</i>
Biliary tract infection	Enteric bacteria (eg., <i>Escherichia coli</i>)
Osteomyelitis	Various bacterial and fungal species – often mixed
Bacterial prostatitis	<i>E. coli</i> and other Gram-negative bacteria
Native valve endocarditis	<i>Viridans</i> Group <i>Streptococci</i>
Cystic fibrosis pneumonia	<i>P. aeruginosa</i> and <i>Burkholderia cepacia</i>
Melioidosis	<i>Pseudomonas pseudomallei</i>
Nosocomial infections	
ICU pneumonia	Gram-negative rods
Sutures	<i>Staphylococcus epidermidis</i> and <i>S. aureus</i>
Exit sites	<i>S. epidermidis</i> and <i>S. aureus</i>
Arteriovenous shunts	<i>S. epidermidis</i> and <i>S. aureus</i>
Schleral buckles	Gram-positive cocci
Contact lens	<i>P. aeruginosa</i> and Gram-positive cocci
Urinary catheter cystitis	<i>S. epidermidis</i> , <i>K. pneumoniae</i> , <i>E. faecalis</i> , <i>Proteus mirabilis</i>
Peritoneal dialysis (CAPD) peritonitis	A variety of bacteria and fungi
IUDs	<i>S. epidermidis</i> , <i>S. aureus</i> , <i>Corynebacterium</i> sp., <i>Micrococcus</i> sp., <i>Enterococcus</i> sp., <i>Candida albicans</i> , Group B <i>Streptococci</i> .
Endotracheal tubes	A variety of bacteria and fungi
Hickman catheters	<i>S. epidermidis</i> and <i>C. albicans</i>
Central venous catheters	<i>S. epidermidis</i> , <i>S. aureus</i> , <i>E. faecalis</i> , <i>K. pneumoniae</i> , <i>P. aeruginosa</i> , <i>C. albicans</i>
Mechanical heart valves	<i>Viridans streptococci</i> , <i>Enterococci</i>
Vascular grafts	Gram-positive cocci
Biliary stent blockage	A variety of enteric bacteria and fungi
Orthopedic devices	<i>Hemolytic streptococci</i> , <i>Enterococci</i> , <i>P. mirabilis</i> , <i>Bacteroides</i> sp., <i>P. aeruginosa</i> , <i>E. coli</i>
Pentile prostheses	<i>S. aureus</i> and <i>S. epidermidis</i>

The development of these agents did not take into account the unique biology of bacterial groups i.e. formation of biofilms. Antibiotic therapy typically reverses the symptoms caused by planktonic cells released from the biofilm, but fails to kill the biofilms [8]. For this reason biofilm infections typically show recurring symptoms after cycles of antibiotic therapy until the sessile population is surgically removed from the body. Planktonic bacterial cells are released from biofilms and this is a natural pattern of programmed detachment. Thus, biofilms can act as ‘niduses’ of acute infection. It is likely that biofilms evade anti microbial challenges by multiple mechanisms [1].

1. Failure of an agent to penetrate the full depth of the biofilm.
2. At least some of the cells in a biofilm experience nutrient limitation and therefore exist in a slow growing or starved state and these cells are not very susceptible to many antimicrobial agents.
3. Some of the cells in a biofilm adopt a distinct and protected biofilm phenotype which is not a response to nutrient

limitation but it is a biologically programmed response to growth on a surface.

***Pseudomonas aeruginosa* Biofilms**

P. aeruginosa is the principal pathogen in the lungs of patients with cystic fibrosis (CF). Chronic colonization by this bacteria leads to progressive lung damage and eventually respiratory failure and death in most CF patients. In *P. aeruginosa*; a complex quorum sensing hierarchy plays a central role in the regulation of virulence and contributes to the late stages of biofilm maturation. *P. aeruginosa* possess two AHL – dependent quorum sensing systems, termed Las RI and RhlR1. Las 1 and Rhl1 are lux homologs that direct the synthesis of N-(3-oxododecanoyl) homoserine lactone (3-oxo – (12-HSL) and N-butanoylhomoserine lactone (C4-HSL). The target genes regulated via las and rhl overlap considerably and recently a third Lux R homolog (Qsc R) has been identified that further modulates their expression. Apart from AHLs, *P. aeruginosa* also produces a third quorum sensing signal

molecule which is essential for the expression of many rhl – dependent phenotypes as well as biofilms development [9].

Antibiotic therapy in patients colonized with *P. aeruginosa* often gives a measure of relief from symptoms but fails to cure the beset ongoing infection. This is because the antibiotic therapy cannot eliminate the antibiotic resistant sessile biofilm communities.

Staphylococcal Biofilms

The genetic and molecular basis of biofilm formation in *staphylococci* is multifaceted. The ability to form a biofilm affords at least two properties: the adherence of cells to a surface and accumulation to form multilayered cell clusters. A trade mark is the production of the slime substance PIA, a polysaccharide composed of beta – 1,6 – linked N-acetyl glucosamines with partly diacetylated residues, in which the cells are embedded and protected against the host's immune defence and antibiotic treatment. Mutations in the corresponding biosynthesis genes (*ica* operon) lead to a pleiotropic phenotype; the cells are biofilm and haemagglutination negative, less virulent and less adhesive on hydrophilic surfaces. *ica* expression is modulated by various environmental conditions, appears to be controlled by Sig B and can be turned on and off by insertion sequence (IS) elements.

Proteins have been identified that are also involved in biofilm formation such as the accumulation-associated protein (AAP), the clumping factor A (Clf A), the staphylococcal surface protein (SSP1) and the biofilm associated protein (Bap). Intercellular adhesions within biofilms of *Staphylococcus epidermidis*, a major cause of medical device related infections, is mediated by the PIA [10].

Dental Biofilms

Dental biofilms, more commonly called plaque, are probably the most well studied natural biofilm in humans. Development of dental biofilms follows a sequence of events and involves hundreds of species of bacteria. After a good dental cleaning, tooth enamel becomes coated with a variety of proteins and glycoproteins of host origin. This coating is called as acquired pellicle. Then the primary colonizers, first *streptococci* and later actinomycetes, colonize the surface of the teeth by adhesion molecules and pili.

The bacteria on the pellicle undergo cell to cell interaction via quorum sensing. A number of *streptococci*, including *Streptococcus mutans* and related organisms, begin to synthesize insoluble glucan via glucan binding protein. Bridge bacteria (members of the genus *Fusobacterium*) form aggregates with primary colonisers. The late colonisers form aggregate with bridge bacteria. At this point of time, the biofilm consists primarily of nonpathogen. However, in the presence of dietary sucrose and other carbohydrate, acids are produced via fermentation, which leads to demineralisation of the tooth enamel, over the time, caries. If the plaque is allowed to remain undisturbed on the teeth for several days, the microbial flora

continues to change. The last colonisers of the biofilm are considered pathogenic because of their role in periodontal disease. The most important pathogens include *Porphyromonas gingivalis*, *Bacteriodes forsythus*, *Actinobacillus actinomycetemcomitans* and *Treponema denticola* [2,11].

Candida Biofilms

Most manifestations of candidiasis are associated with the formation of *Candida* biofilms on surfaces and it is also associated with infections at both mucosal and systemic sites.

Candida biofilms share several properties with bacterial biofilms. *C. albicans* biofilm formation has 3 distinct developmental phases: early (0-11 h), intermediate (12-30 h) and mature (38-72h) [12]. The detailed structure of mature *C. albicans* biofilms consists of a dense network of yeast, hyphae and pseudohyphae. This mixture of yeast, hyphae and matrix material is not seen when the organisms is grown in liquid culture or on an agar surface, which suggests that morphogenesis is triggered when an organisms contacts a surface [13-15].

Studies showed that *C. dubliniensis* has the ability to adhere to and form biofilms with structural heterogeneity and typical microcolony and water channel architecture similar to bacterial biofilms and *C. albicans* biofilms [15,16].

Indwelling intravascular catheters represent a risk factor that is associated with nosocomial *Candida* infections. The devices become colonised by the microorganisms that form a biofilm of cells, the detachment of which can result in septicaemia [17-19].

Antifungal drug resistance is quickly becoming a major problem. Major genes that contribute to drug resistance in *C. albicans* and *C. dubliniensis* are CDR genes (CDR 1 and CDR 2) and MDR genes. These genes have been demonstrated to be upregulated during biofilm formation and development [12,13,17].

Detection of Biofilms

With the emergence of biofilm associated diseases, there are considerable diagnostic problems for the clinical laboratory. These problems can be classified into five categories: false negative cultures, visible but non cultivable organisms, underestimated or low colony count, inappropriate specimen and loss of or decreased antimicrobial susceptibility. Biofilms are resilient, adherent and with EPS, quite resistant to culturing by swabs.

Detection in Loose Needle Connectors

1. Cooper et al. [20] developed a Gram staining technique of the catheter tips, the technique depends on optical properties of the different catheters but it is time consuming since it requires the microscopical examination of at least 200 oil immersion fields.
2. By direct acridine orange staining of the catheter tips [21].
3. By scanning electron microscope.
4. Maki et al. [22] developed a semiquantitative method for culturing vascular cannulas on solid media.

Methods

Tissue Culture Plate Method (TCP)

The TCP assay described by Christensen et al. [23] is most widely used and is considered a standard test for detection of biofilm formation. The microorganisms are grown in polystyrene tissue culture plates for 24 hours then after washing fixed with sodium acetate (2%) and stained with crystal violet (0.1% w/v). Biofilm formation is detected by measuring optical density with ELISA reader.

Tube Method [24]

It is a qualitative assessment of biofilm formation where the microorganisms are grown in trypticase soy broth with 1% glucose in tubes for 24 hours. The tubes are then decanted and washed with PBS (phosphate buffer saline) and stained with crystal violet (0.1%). The tubes are then washed and dried and biofilm formation is considered positive when a visible film lines the wall and bottom of the tube.

Congo Red Agar Method (CRA) [25]

The microorganisms are grown on brain heart infusion agar with 5% sucrose and congo red. Positive results are indicated by black colonies with a dry crystalline consistency.

Bioluminescent Assay

Attenuated Total Reflecting Spectroscopy (ATR)

It has been used to monitor the conditioning films that are an early harbinger of biofilm formation.

Piezoelectric Sensors

Such as quartz with crystal microbalances monitor frequency shifts as mass accumulates on the sensor surface.

Possible Strategies for Eradication of Biofilms [2,26,27]

For eradication, combination of strategies have been used:

1. Mechanical disruption / removal (sonication);
2. Immune modulation (Azithromycin and low dose doxycycline);
3. Antimicrobial agents (silver and tobramycin);
4. Amphotericin B lipid formulations and the Echinocandins against the *Candida* biofilms.

The effective control will require a concerted effort to develop therapeutic agents that target the biofilm phenotype and community signalling – based agents that prevent the formation, or promote the detachment of biofilms.

References

1. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: A common cause of persistent infections. *Science* **1999**;284:1318-22.
2. John G.T., Donale C.L. Biofilms: architects of disease. In: Connie R.M., Donald C.L., George M., editors. *Textbook of diagnostic microbiology*. 3rd ed. Saunders **2007**; p. 884-95.
3. Victoria W., Serralra B.S., Catherine H., et al. Life styles of bacteria in wounds: presence of biofilms. *Wounds* **2001**;13(1):29-34.
4. Lam J., Chan R., Lam K., Costerton J.W. Production of mucoid microcolonies by *Pseudomonas aeruginosa* within infected lungs in cystic fibrosis. *Infect Immun* **1980**;28:546-56.
5. Nickel J.C. Bacterial biofilms in urology. *Infect Urol* **1998**;11(6):169-75.
6. Ward K.H., Olson M.E., Lam K., Costerton J.W. Mechanism of persistent infection associated with peritoneal implant. *J Med Microbiol* **1992**;36:406.
7. Cochrane D.M.G. Immune response to bacterial biofilms. *Med Microbiol J* **1988**;27:255.
8. Sritharan M., Sritharan V. Emerging problems in the management of infectious diseases: the Biofilms. *Indian J Med Microbiol* **2004**;22(3):140-2.
9. Hardie K.R., Badwin T., William P. Molecular basis of bacterial adaptation to pathogenic life style. In: Borriello SP, Murray PR, Funke G, editors. *Topley and Wilson's Microbiology and Microbial infections*. 10th ed. Hodder Arnold, ASM Press, **2005**:147-82.
10. Gotz F. *Staphylococcus* and biofilms. *Mol Microbiol* **2002**;43(6):1367-78.
11. Rosan B. Dental plaque formation. *Microbes Infect* **2000**; 2: 1599.
12. Chandra J., Kuhn D.M., Mukherjee P.K., et al. Biofilm formation by fungal pathogen *C. albicans*: dev, architec, and drug (R). *J Bacteriol* **2001**;183:5385-94.
13. Douglas L.J. Medical importance of biofilms in *Candida* infection. *Rev Iberam Micol* **2002**;19:139-43.
14. Douglas L.J. *Candida* biofilms and their role in infection. *Trends Microbiol* **2003**;11:30-6.
15. Ramage G., Vande Walle K., Wickes B.L., Lopez Ribod J.L. Biofilm formation by *Candida dubliniensis*. *J Clin Microbiol* **2001**;39:3234-40.
16. O'Toole G.A., Kaplan H.B., Kolter R. Biofilm formation as microbial development. *Annu Rev Microbiol* **2000**;54:49-79.
17. Ramage G., Bachmann S., Patterson T.F., et al. Investigation of multidrug efflux pumps in relation to fluconazole resistance in *Candida albicans* biofilms. *J Antimicrob Chemother* **2002**;49:973-80.
18. Adam B., Baillie G.S., Douglas L.J. Mixed species biofilms of *Candida albicans* and *Staphylococcus epidermidis*. *J Med Microbiol* **2002**;51:344-9.
19. Donlan R.M. Biofilms: microbial life on surfaces. *Emerg Infect Dis* **2002**;8:1-19.
20. Cooper G.L., Hopkins C.C. Rapid diagnosis of intravascular-catheter associated infection by direct Gram staining of catheter segments. *N Engl J Med* **1985**;312:1142-7.
21. Zufferey J., Rime B., Francioli P., Bille J. Simple method for rapid diagnosis of catheter – associated infection by direct Acridine Orange staining of catheter tips. *J Clin Microbiol* **1988**;26(2):175-7.
22. Maki D.G., Weise C.E., Sarafin H.W. Semiquantitative culture method for identifying intravenous – catheter related infection. *N Engl J Med* **1977**;296:1305-9.
23. Christensen G.D., Simpson W.A., Yonger J.A., et al. Adherence of coagulase negative *staphylococci* to plastic tissue cultures: a quantitative model for the adherence of *staphylococci* to medical device. *J Clin Microbiol* **1985**;22:996-1006.
24. Christensen G.D., Simpson W.A., Bisno A.L., Beachey E.H. Adherence of slime – producing strains of *Staphylococcus epidermidis* to smooth surfaces. *Infect Immun* **1982**;37:318-26.
25. Freeman D.J., Falkiner F.R., Keane C.T. New method for detecting slime production by coagulase negative *staphylococci*. *J Clin Pathol* **1989**;42:872-4.
26. Bachmann S.P., Vande Walle K., Ramage G., et al. *In vitro* activity of casofungin against *Candida albicans* biofilms. *Antimicrobiol Agents Chemother* **2002**;46:3591-6.
27. Kuhn D.M., George T., Chandra J., et al. Antifungal susceptibility of *Candida* biofilms: unique efficacy of amphotericin B lipid formulation and echinocandins. *Antimicrobial Agents Chemother* **2002**;46:1773-80.